Previous 10 | Next 10 |
CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corpo...
Community Bancorp Inc Vermont (CMTV) is expected to report for Q4 2023 CISO Global, Inc (CISO) is expected to report for Q4 2023 TCTM Kids IT Education Inc. (TCTM) is expected to report for quarter end 2023-12-31 Generation Income Properties Inc. (GIPR) is expected to report for quart...
2024-03-07 15:31:36 ET More on Vaxxinity Seeking Alpha’s Quant Rating on Vaxxinity Historical earnings data for Vaxxinity Financial information for Vaxxinity Read the full article on Seeking Alpha For further details see: Vaxxinity gains af...
LISBON, Portugal, March 07, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ: VAXX ), a U.S. company pioneering the development of a new class of medicines, announced positive clinical data from its UB-312 program in Parkinson’s disease (PD) presented by Jean-Cosme Dodart, PhD, SVP of ...
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of VXX-401 is ongoing, with topline results expected mid-2024. CAPE CANAVERAL, Fla.,...
CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson’s disease and preclinical data from its ant...
CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced a research collaboration with the University of Florida’s (UF) Center for Translational Research in Neurodegen...
CAPE CANAVERAL, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced a collaboration with the University of Central Florida (UCF) to advance space medicine research. The research, fu...
CAPE CANAVERAL, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present an update on the Company and its pipeline at the ...
CAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and executives will present and participate in meetings at three upcoming medical and investor co...
News, Short Squeeze, Breakout and More Instantly...
UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living. Data demonstrates target engagement and immunogenicity of the active immunotherapy UB-312 targeting pathological ...
BowFlex Inc. (BFXXQ) is expected to report for Q4 2024 Leafbuyer Technologies Inc (LBUY) is expected to report for Q3 2024 Pacific Booker Minerals Inc (PBMLF) is expected to report for Q1 2025 BZAM Ltd Com (BZAMF) is expected to report for Q1 2024 MJ Holdings Inc (MJNE) is expecte...
Orbital Infrastructure Group Inc. (OIGBQ) is expected to report for Q1 2024 OFS Credit Company Inc. (OCCI) is expected to report for Q2 2024 KBC Groupe NV ADR (KBCSY) is expected to report for Q1 2024 Daikin Industries Ltd ADR (DKILY) is expected to report $0.11 for Q4 2024 Invita...